{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Bobart SA"],"funding":["National Institute of Diabetes and Digestive and Kidney Diseases","National Institutes of Health"],"pubmed_abstract":["Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%-80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions (e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D'Hebron (Barcelona), and the Colu"],"journal":["Clinical journal of the American Society of Nephrology : CJASN"],"pagination":["CJN.05480421"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8729491"],"repository":["biostudies-literature"],"pubmed_title":["Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study."],"pmcid":["PMC8729491"],"funding_grant_id":["2P30DK063608-16","R01DK126959","UM1DK100876"],"pubmed_authors":["Giesen CD","Bomback AS","Sethi S","Soler MJ","Zand L","Han H","Roman JCL","Andrades Gomez C","Bobart SA","Fervenza FC","Tehranian S","De Vriese AS"],"additional_accession":[]},"is_claimable":false,"name":"Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study.","description":"Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%-80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions (e.g., autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively. These data have not been externally validated. The clinical and pathologic characteristics of patients with a positive anti-phospholipase A2 receptor antibody test at the Mayo Clinic, the University Hospital Vall D'Hebron (Barcelona), and the Colu","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-05T09:43:03.942Z","creation":"2025-04-05T09:43:03.942Z"},"accession":"S-EPMC8729491","cross_references":{"pubmed":["34782349"],"doi":["10.2215/cjn.05480421","10.2215/CJN.05480421"]}}